• 7024 malaria professionals are enjoying the free benefits of MalariaWorld today
Home › artemisone

artemisone

Pharmaceutical Nanotechnology: Absorption of the novel artemisinin derivatives artemisone and artemiside: Potential application of Pheroid™ technology

Submitted by patrick sampao on June 28, 2011 - 12:41
Tags:
Author(s): 
J. Dewald Steyn, Lubbe Wiesner, Lissinda H. du Plessis, Anne F. Grobler, Peter J. Smith, Wing-Chi Chan, Richard K. Haynes, Awie F. Kotzé
Reference: 
International Journal of Pharmaceutics, Volume 414, Issues 1-2, 29 July 2011, Pages 260-266
Access: 
Click here to go to the Journal
Contact email: 
dewald.steyn@nwu.ac.za

Pharmacokinetic models were constructed for artemisone and artemiside in Pheroid™ vesicle formulations. The compounds were administered at a dose of 50.0 mg/kg bodyweight to C57 BL/6 mice via an oral gavage tube and blood samples were collected by means of tail-bleeding.

_____________________________________________________________

Artemisone Uptake in Plasmodium falciparum-Infected Erythrocytes

Submitted by Kabogo on January 25, 2011 - 06:42
Tags:
Author(s): 
Sophie Pooley, Farrah A. Fatih, Sanjeev Krishna, Michael Gerisch, Richard K. Haynes, Ho-Ning Wong, and Henry M. Staines
Reference: 
Antimicrobial Agents and Chemotherapy, February 2011, p. 550-556, Vol. 55, No. 2
Access: 
Click here to go to the Journal
Contact email: 
hstaines@sgul.ac.uk

Artemisone is one of the most promising artemisinin derivatives in clinical trials.

_____________________________________________________________

Open Access | Artemisone effective against murine cerebral malaria

Submitted by Kabogo on August 11, 2010 - 12:34
Tags:
Author(s): 
Waknine-Grinberg JH, Hunt N, Bentura-Marciano A, McQuillan JA, Chan H, Chan W, Barenholz Y, Haynes RK, Golenser J
Reference: 
Malaria Journal 2010, 9:227 (9 August 2010)
Access: 
Click here to go to the full article
Contact email: 
jhwaknine@gmail.com

Altogether, the results support the use of artemisone for combined therapy of CM.

_____________________________________________________________
Syndicate content